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Abstract
Background: Data accumulated from mouse studies and in vitro studies of human arteries
support the notion that soluble intercellular adhesion molecule-1 (sICAM-1) and monocyte
chemoattractant protein-1 (MCP-1) play important roles in the inflammation process involved in
atherosclerosis. However, at the population level, the utility of sICAM-1 and MCP-1 as biomarkers
for subclinical atherosclerosis is less clear. In the follow-up exam of the NHLBI Family Heart Study,
we evaluated whether plasma levels of sICAM-1 and MCP-1 were associated with coronary artery
calcification (CAC), a measure of the burden of coronary atherosclerosis.
Methods:  CAC was measured using the Agatston score with multidetector computed
tomography. Information on CAC and MCP-1 was obtained in 2246 whites and 470 African
Americans (mean age 55 years) without a history of coronary heart disease (CHD). Information on
sICAM-1 was obtained for white participants only.
Results: In whites, after adjustment for age and gender, the odds ratios (ORs) of CAC (CAC > 0)
associated with the second, third, fourth, and fifth quintiles of sICAM-1 compared to the first
quintile were 1.22 (95% confidence interval [CI]: 0.91–1.63), 1.15 (0.84–1.58), 1.49 (1.09–2.05), and
1.72 (1.26–2.36) (p = 0.0005 for trend test), respectively. The corresponding ORs for the second
to fifth quintiles of MCP-1 were 1.26 (0.92–1.73), 0.99 (0.73–1.34), 1.42 (1.03–1.96), and 2.00
(1.43–2.79) (p < 0.0001 for trend test), respectively. In multivariable analysis that additionally
adjusted for other CHD risk factors, the association of CAC with sICAM-1 and MCP-1 was
attenuated and no longer statistically significant. In African Americans, the age and gender-adjusted
ORs of CAC associated with the second and third tertiles of MCP-1 compared to the first tertile
were 1.16 (0.64–2.08) and 1.25 (0.70–2.23) (p = 0.44 for trend test), respectively. This result did
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not change materially after additional adjustment for other CHD risk factors. Test of race
interaction showed that the magnitude of association between MCP-1 and CAC did not differ
significantly between African Americans and whites. Similar results were obtained when CAC ≥ 10
was analyzed as an outcome for both MCP-1 and sICAM-1.
Conclusion:  This study suggests that sICAM-1 and MCP-1 are biomarkers of coronary
atherosclerotic burden and their association with CAC was mainly driven by established CHD risk
factors.
Background
Response of the endothelium to injuries to the arterial
wall, including increased expression of inflammatory
markers, is a well-recognized component of atherosclero-
sis [1]. Critical steps involved in the early phase of athero-
sclerosis include recruitment of leukocytes from the
circulation, their attachment to the vascular surfaces and
transendothelial migration [2,3]. Monocyte chemoattract-
ant protein-1 (MCP-1) is a chemokine that plays an
important role in recruiting circulating monocytes to sites
of atherosclerotic lesions [4]. It is produced by a variety of
cells including endothelial cells, smooth muscle cells, and
macrophages [4]. Intercellular adhesion molecule-1
(ICAM-1), which belongs to the immunoglobulin super-
family, is constitutively expressed on vascular endothelial
cells and leukocytes and can be induced on vascular
smooth muscle cells [5,6]. ICAM-1, present on the vascu-
lar endothelium, participates in leukocyte adhesion and
facilitates leukocyte transendothelial migration [2,7]. Sol-
uble ICAM-1 (sICAM-1) is a circulating form of ICAM-1
and has been shown to reflect cell surface expression of
ICAM-1 in human vascular endothelial cells [8]. The main
mechanism responsible for release of sICAM-1 is believed
to be proteolytic cleavage of ICAM-1 from cell membranes
[9].
Data accumulated from in vitro and mouse studies sup-
port the notion that sICAM-1 and MCP-1 play important
roles in atherogenesis. In human coronary atherosclerotic
plaques, ICAM-1 is strongly expressed by endothelial cells
and macrophages [10]. An examination of human arteries
has revealed detectable MCP-1 levels in multiple cell types
in atherosclerotic plaques but little expression in normal
vessels [11]. Studies in low-density lipoprotein (LDL)
receptor- or APOE-knockout mice have shown that a defi-
ciency of ICAM-1 or MCP-1 reduced atherosclerosis [12-
14].
Prospective epidemiological studies have found increased
risk of incident or recurrent coronary heart disease (CHD)
associated with higher baseline levels of sICAM-1 and
MCP-1 [15-18], but it is unclear whether sICAM-1 and
MCP-1 reflect the burden of subclinical coronary athero-
sclerosis. Coronary artery calcification (CAC) measured
by computed tomography (CT) is a marker of the burden
of coronary atherosclerosis and is closely correlated with
the extent of total coronary atheroma as measured histo-
logically [19]. There have been limited epidemiologic
studies examining the relation between CAC, MCP-1, and
sICAM-1 [20-22]. Specifically, the association of CAC
with MCP-1 was investigated in only one population-
based study [20], and with sICAM-1 in two small studies
of selected individuals but with somewhat inconsistent
results [21,22]. Moreover, the study populations included
in those studies were either predominantly white popula-
tions or populations of mixed ethnicity and there were no
race-specific data or tests of race interaction in this regard.
In this study, we investigated whether CAC was associated
with sICAM-1 and MCP-1 in a large population-based
biracial sample free of clinical CHD.
Methods
Study population
The NHLBI Family Heart Study (FHS) is a population-
based family study investigating the genetic and non-
genetic determinants of CHD, subclinical atherosclerosis,
and cardiovascular disease risk factors [23]. About half of
the families in the study were ascertained randomly and
the other half selected for a positive family history of
CHD. Both samples were recruited through probands in
the Framingham Heart Study (Framingham, MA), the
Utah Health Family Tree Study (Salt Lake City, UT), and
the Atherosclerosis Risk in Communities (ARIC) Study
(Minneapolis, MN and Forsyth County, NC). Probands,
their spouses, parents, siblings, and children who were
over 25 years old were invited to participate.
In its follow-up examination conducted between 2002
and 2003, the FHS recruited about 1/3 of the original fam-
ilies to participate in a second examination to measure
calcification of the coronary arteries by cardiac multide-
tector CT. These families were the largest FHS families and
previously genotyped for anonymous genetic markers
spanning across the genome. In addition, a new center
was established at the University of Alabama-Birmingham
to recruit African-American probands from the Hyperten-
sion Genetic Epidemiology Network Study and their first-
degree relatives [24]. All of the data reported in the study
were obtained in the follow-up examination. This study
was approved by institutional review board at each partic-BMC Cardiovascular Disorders 2007, 7:30 http://www.biomedcentral.com/1471-2261/7/30
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ipating field center and the coordinating center. Written
informed consent was obtained from each participant.
Study procedures
A clinical examination was performed according to a
standardized protocol. Participants were asked to fast for
twelve hours prior to their arrival at the study center where
their blood was drawn for laboratory tests. During the
clinic visit, a standardized interview was conducted to
obtain information on medical history and personal
behaviors, and anthropometric measurements were made
with the participant wearing a scrub suit or examination
gown. Blood pressure was measured after participants had
rested seated for 5 minutes and taken as the average of the
second and third of three measurements using a Dinamap
device. Participants were asked to bring all medications
taken in the previous 4 weeks and the interviewer tran-
scribed this information. Ever smoking was defined as
having smoked at least 100 cigarettes in lifetime. Subjects
were categorized into never smokers, former smokers and
current smokers. Never smokers were subjects who
answered 'no' to the ever-smoking question. Former
smokers were subjects who were ever smokers and had
quit smoking at the time of the interview. Pack-years of
smoking were calculated as the number of packs of ciga-
rettes smoked per day multiplied by the number of years
the participant smoked. Use of hormone replacement
therapy was defined as having taken or used pills, skin
patches, or shots for hormone replacement therapy in the
past month.
Measurements of fasting plasma triglycerides, HDL, and
total cholesterol were obtained using standard laboratory
methods. LDL cholesterol was calculated using the Friede-
wald formula for subjects with triglycerides concentra-
tions  ≤ 400 mg/dL. For subjects with higher levels of
triglycerides (n = 52), LDL cholesterol was calculated by
an equation developed in 123 FHS participants of the 1st
examination who were free of prevalent CHD, had triglyc-
erides > 400 and had LDL cholesterol measured on EDTA
plasma by ultracentrifugation LDL cholesterol = 55.7+(-
0.358*age)+(4.232*gender)+(0.532*total choles-
terol)+(-0.160*HDL cholesterol)+ [-0.614*(triglycerides/
5)], where gender is coded as men = 1 and women = 2].
This equation explained 74% of variation in LDL choles-
terol and performed better than the Friedewald formula
according to correlation coefficient between measured
and predicted LDL cholesterol (0.86 vs 0.84), median dif-
ference (-0.55 vs -5.0) and maximum difference (-42/70
vs -75/95). Hypertension was defined as systolic blood
pressure (SBP) ≥ 140 mmHg, diastolic blood pressure
(DBP) ≥ 90 mmHg, or treatment for hypertension. Diabe-
tes was defined by the American Diabetes Association cri-
teria (fasting glucose ≥ 126 mg/dL or use of hypoglycemic
medication). CHD was defined by self-reported history of
myocardial infarction, coronary angioplasty, or coronary
bypass surgery.
Measurement of calcified atherosclerotic plaque in the 
coronary arteries
Cardiac CT examinations were performed using the proto-
col and quality control procedures employed in the Multi-
Ethnic Study of Atherosclerosis (MESA) and Coronary
Artery Risk Development in Young Adults (CARDIA) [25].
In brief, biweekly calibration scans documenting the sta-
bility of each CT system's calibration to water and 3 con-
centrations of calcium were obtained to monitor accuracy,
precision, and temporal drift. On-site training and certifi-
cation were performed. Technical parameters were: 120
KV, 106 mAs, 2.5 mm slice collimation, prospective ECG
gating at 50% of the R-R interval, 0.5 or 0.8 second gantry
rotation, a partial scan reconstruction resulting in a tem-
poral resolution of between 250–500 msec and a 35 cm
display field-of-view. All participants were imaged with a
calcium calibration standard within the imaging field
(Image Analysis, Columbia, KY). For participants weigh-
ing 100 kg (220 lbs) or greater, the milliampere setting
was increased by 25%. The scan through the heart was
performed twice sequentially with a 1-minute interval.
The effective radiation exposure for the average partici-
pant was 1.5 mSv for men and 1.9 mSv for women.
Calcified atherosclerotic plaque in the epicardial coronary
arteries was analyzed centrally at Wake Forest University
Health Sciences, Winston Salem, by trained image ana-
lysts using dedicated hardware and software covering the
entire heart (GE Healthcare Advantage Windows Worksta-
tion with SmartScore, Waukesha, WI). Analysts measured
calcified plaque in the epicardial coronary arteries with
the program calculating a total calcium or Agatston score
modified to account for slice thickness using a 130 CT
number threshold and a minimum lesion size of 0.9 mm
(i.e., 2 pixel connectivity filter). The total calcium scores
from the first and second CT scan series were then aver-
aged, and the average score was used in the analysis.
Measurement of inflammation biomarkers
Inflammation biomarkers were measured at the Depart-
ment of Pathology and Biochemistry, University of Ver-
mont. MCP-1 was measured in citrated plasma using an
ultra-sensitive ELISA assay (Quantikine Human MCP-1
Immunoassay; R&D Systems, Minneapolis, MN). Inter-
batch coefficients of variation (CVs) ranged from 4.6 –
6.7%. sICAM-1 was measured in citrated plasma by an
ELISA assay (Parameter Human sICAM-1 Immunoassay;
R&D Systems, Minneapolis, MN). The laboratory CV was
5.0%. C-reactive protein (CRP) was measured in SCAT-I
plasma by a BNII nephelometer (Dade Behring, Deerfield,
IL) utilizing a particle enhanced immunonepholometric
assay. Inter-batch CVs ranged from 2.1% – 5.7%.BMC Cardiovascular Disorders 2007, 7:30 http://www.biomedcentral.com/1471-2261/7/30
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Statistical analysis
There were 3111 subjects who had complete information
on CAC score, sICAM-1 and MCP-1. We excluded 395
subjects who met the following criteria: 1) other race
groups than white or African American (n = 18); 2) Afri-
can Americans from the North Carolina field center or
whites from the Birmingham center (n = 13); 3) prevalent
CHD or history of coronary revascularization procedures
at the time of the study (n = 351); 4) outliers with log-
transformed sICAM-1 or MCP-1 values greater than or less
than 5 standard deviations from the corresponding mean
(n = 13). Thus, 2716 subjects (2246 whites and 470 Afri-
can Americans) were included in the analyses. We
excluded subjects with prevalent CHD or history of coro-
nary revascularization procedures because the focus of the
study is on subclinical coronary atherosclerosis. In addi-
tion, subjects with prevalent CHD may have undergone
treatment that could affect the variables of interest.
It was reported that a K29M mutation at the ICAM-1 gene
causes low detectability for serum sICAM-1 level as meas-
ured by R&D systems assay which uses the BBE1B anti-
body [26]. This mutation occurred at a frequency of 20%
in African Americans and 0.4% in Caucasians [26]. There-
fore, the 470 African-American participants were excluded
from the analysis of sICAM-1. Accordingly, the study pop-
ulation for MCP-1 comprised both whites and African
Americans and that for sICAM-1 comprised whites only.
Comparison of distributions of demographic and clinical
characteristics between those with and without CAC was
made by generalized estimating equations (GEE), which
account for familial relatedness. Spearman rank order cor-
relations were used to assess the association of sICAM-1
and MCP-1 with continuous covariates. The association of
categorical covariates with sICAM-1 and MCP-1 was eval-
uated in GEE in which natural log-transformation was
performed for sICAM-1 and MCP-1 to normalize the trait
distributions. Accordingly, sICAM-1 and MCP-1 are pre-
sented as geometric means with 95% confidence intervals.
All of the above and subsequent analyses for MCP-1 were
stratified by race. To investigate the association between
the inflammation markers and CAC, we estimated the
odds ratio (OR) of presence of CAC across sICAM-1 and
MCP-1 categories by GEE models and computed p values
for trend using a continuous variable that was assigned
the median value of sICAM-1 or MCP-1 in each exposure
category. In whites, sICAM-1 and MCP-1 were grouped
into quintile levels, while tertile categories were used for
MCP-1 in African Americans due to smaller sample size.
Furthermore, we applied tertile cutpoints of MCP-1 in
African Americans to whites and evaluated whether the
ORs of CAC associated with each level of MCP-1 differed
between African Americans and whites. Confounding was
assessed in 3 sequential models: no adjustment; partial
adjustment: adjusted for age and gender; multivariable
adjustment: adjusted for age, gender, field center, BMI,
SBP, diabetes, HDL and LDL cholesterol, triglycerides,
physical activity index (met-min/week), hours of televi-
sion watched/day, smoking status (current, former,
never), pack-years of smoking, current alcohol consump-
tion, and hormone replacement therapy. We initially
tested the interaction of sex on the association between
inflammation markers and CAC in the above GEE analy-
ses, and did not observe significant interaction. Therefore,
the above analyses were conducted with men and women
combined. In addition, we tested whether the association
of CAC with sICAM-1 and MCP-1 differed across age
groups (tertile groups in whites and median groups in
African Americans) and did not observe significant age
differences in either race group.
Since presence of CAC according to Agatston score > 0
may be subject to measurement errors due to tissue-asso-
ciated artifacts, we chose two different criteria in the above
analyses for defining the presence of CAC (CAC score > 0
and CAC score ≥ 10). The cut point of CAC score ≥ 10 was
chosen to be consistent with other studies addressing sim-
ilar research questions [20].
Finally, among whites subjects with detectable CAC (CAC
> 0), a linear regression model implemented in GEE was
used to test for trend with log-transformed CAC score as
the dependent variable and sICAM-1 and MCP-1 as inde-
pendent variables. The natural log-transformed CAC score
was approximately normally distributed. This analysis
was not conducted for MCP-1 in African Americans due to
limited number of African Americans with CAC > 0. All
analyses were performed using SAS version 8.2 (SAS Insti-
tute).
Results
In whites, the mean ± SD, median and inter-quartile range
for sICAM-1 (ng/ml) are 246.7 ± 78.6, 231.3, and
195.1~281.6, respectively, and for MCP-1 (pg/ml) were
189.1 ± 60.5, 180.2, and 149.9~218.9, respectively. In
African Americans, the mean ± SD, median and inter-
quartile range for MCP-1 (pg/ml) were 174.3 ± 68.3,
168.2, and 136.5~195.0, respectively. The mean level of
MCP-1 was significantly lower in African Americans than
in whites, and this difference persisted after adjusting for
age, gender, BMI, SBP, diabetes, HDL and LDL choles-
terol, triglycerides, physical activity index (met-min/
week), hours of television watched/day, smoking status
(current, former, never), pack-years of smoking, current
alcohol consumption, and hormone replacement therapy
(p < 0.01). The prevalence of hypertension was 39.3% in
whites and 75.1% in African Americans.BMC Cardiovascular Disorders 2007, 7:30 http://www.biomedcentral.com/1471-2261/7/30
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Table 1 shows demographic and clinical characteristics of
subjects by CAC status. Compared to subjects with zero
calcium score, subjects with detectable calcium were older
and more likely to be males, current or former smokers,
and have hypertension and diabetes. All of the other risk
factors, except race, LDL cholesterol, current alcohol con-
sumption, and aspirin use, were also significantly associ-
ated with CAC status.
Table 2 presents partial Spearman correlation coefficients
of MCP-1 and sICAM-1 with continuous covariates. Due
to smaller sample size, the correlations between MCP-1
and the continuous covariates were generally less signifi-
cant in African Americans than in whites. However, the
pattern of correlations agreed between the two racial
groups for most of the covariates except that MCP-1 was
less strongly associated with BMI, SBP, and physical activ-
ity index in African Americans.
Table 3 presents adjusted geometric means of MCP-1 and
sICAM-1 by categorical covariates. The pattern of associa-
tions between MCP-1 and the categorical covariates were
consistent between the two racial groups. It is interesting
to note that at each level of the categorical variables, mean
MCP-1 was consistently lower in African Americans than
in whites, further confirming our earlier observation that
African Americans had lower levels of MCP-1 compared
to whites.
Tables 4 and 5 present ORs of presence of CAC by quin-
tiles of sICAM-1 and MCP-1, respectively, in whites. Based
on a criterion of CAC score > 0, coronary calcification was
present in 55% (1239) of subjects. When the cut point
was raised to CAC ≥ 10, the prevalence of CAC was 37%.
There was a significant and positive association between
the presence of CAC, sICAM-1 and MCP-1 before and
after adjusting for age and gender (Tables 4 and 5). This
association was consistent for both the CAC > 0 and CAC
≥ 10 criteria. However, after additionally adjusting for
Table 1: Demographic and clinical characteristics by CAC status: mean ± SD or percentage
Characteristics CAC = 0 (N = 1250) CAC > 0 (N = 1466) p
Age, years 48.8 ± 10.6 60.4 ± 11.9 <0.0001
Females, % 71.4 51.3 <0.0001
African Americans, % 19.4 15.5 0.33
Body mass index, kg/m2 28.5 ± 6.1 30.2 ± 6.2 <0.0001
Waist circumference, cm 94.7 ± 16.1 102.9 ± 15.9 <0.0001
Systolic blood pressure, mm Hg 115.6 ± 18.0 127.0 ± 21.4 <0.0001
Diastolic blood pressure, mm Hg 69.3 ± 10.2 72.3 ± 10.4 <0.0001
Hypertension, % 31.3 57.6 <0.0001
Diabetes, % 6.9 15.4 <0.0001
HDL-C, mg/dL 52.2 ± 14.8 48.9 ± 14.3 <0.0001
Triglycerides*, mg/dL 124.4 ± 84.8 145.6 ± 93.0 <0.0001
LDL cholesterol, mg/dL 112.1 ± 32.7 113.7 ± 33.9 0.18
CRP*, mg/L 3.87 ± 6.02 4.37 ± 6.69 <0.0001
sICAM-1*†, ng/ml 237 ± 68 255 ± 85 <0.0001
MCP-1*, pg/ml 172.1 ± 56.1 198.9 ± 64.3 <0.0001
Pack-years of smoking*‡ 14.8 ± 16.8 26.5 ± 25.1 <0.0001
Smoking status <0.0001
Current smoker, % 9.9 13.2
Former smoker, % 22.3 34.3
Never smoker, % 67.8 52.5
Current alcohol consumption, % 50.9 51.0 0.29
Hormone replacement therapy§, % 23.4 26.1 0.03
Aspirin use, % 23.3 38.5 0.08
Cholesterol lowing medications, % 8.9 26.4 <0.0001
Hours of TV watched/day 2.40 ± 1.74 2.95 ± 2.06 0.0003
Physical activity index*, met-min/
week
755.7 ± 1107.6 657.6 ± 992.9 0.008
CAC (mean) 0 282.4 ± 655.2 -
CAC [median (IQR)] 0.0 (0.0–0.0) 48.5 (3.5–256.5) -
All statistical comparison was adjusted for age and gender except when age or gender were analyzed as an independent variable; the analysis of 
gender was adjusted for age only;
*Natural log-transformed values were used in the statistical test;
†White participants only: n = 1007 in CAC = 0 group, and 1239 in CAC > 0 group;
‡Current or former smokers only: n = 402 in CAC = 0 group, and 696 in CAC > 0 group;
§Females only: n = 892 in CAC = 0 group, and 752 in CAC > 0 group.BMC Cardiovascular Disorders 2007, 7:30 http://www.biomedcentral.com/1471-2261/7/30
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other CHD risk factors, the association between CAC and
sICAM-1 was no longer significant whether CAC > 0 or
CAC ≥ 10 were analyzed as an outcome (Table 4). In the
multivariable adjustment models, the association
between CAC and MCP-1 was borderline significant for
CAC > 0 and not significant for CAC ≥ 10 (Table 5).
Table 6 presents ORs of presence of CAC by tertiles of
MCP-1 in African Americans, in which the percentage of
CAC > 0 and CAC ≥ 10 was 48% and 31%, respectively.
Similar to whites, MCP-1 was positively associated with
the presence of CAC in unadjusted models. This associa-
tion was no longer significant after adjustment for age and
gender or additional adjustment for other CHD risk fac-
tors. Figure 1 shows prevalence of CAC (%) across MCP-1
tertiles in African Americans in comparison to whites, in
which MCP-1 tertile cutpoints from African Americans
were used to group participants. As shown in Figure 1, the
prevalence of CAC > 0 or CAC ≥ 10 increased with MCP-
1 in a similar fashion between African Americans and
whites; consistent with this observation, tests of interac-
tions did not detect significant interactions of race on the
associations between MCP-1 and CAC in raw (no adjust-
ment), partial or multivariate adjustment models (p >
0.05).
Among whites with CAC > 0, there was a positive trend
between the amount of CAC and levels of sICAM-1 and
MCP-1. However, this association did not reach statistical
significance in either partial or multivariable adjustment
models (data not shown).
The above results did not change materially after we sub-
stituted hypertension for SBP, waist circumference for
BMI, and fasting glucose for diabetes in the multivariable
adjustment models. Finally, since it is of concern that
measurement errors in the estimated LDL cholesterol for
those with triglycerides > 400 mg/dL may affect our ability
to control for confounding, we replaced LDL cholesterol
by total cholesterol in the multivariable analyses and all
results were similar (data not shown).
Discussion
In this large population-based sample free of clinical
CHD, we investigated the association of CAC with MCP-1
in both African Americans and whites, and with sICAM-1
in whites. In whites, we found that sICAM-1 and MCP-1
were significantly and positively associated with presence
of CAC after controlling for age and gender. However, the
observed association was attenuated and no longer statis-
tically significant after additionally adjusting for other
CHD risk factors. In African Americans, the magnitude of
association between MCP-1 and CAC was similar to that
in whites, but less significant due to smaller sample size.
While MCP-1 was significantly lower in African Americans
than whites independently of other CHD risk factors, the
magnitude of associations of MCP-1 with CAC did not
differ between the two racial groups.
The association of MCP-1 with coronary calcification has
been investigated by Deo et al in a population-based sam-
ple of 3,499 adults free of CHD [20]. They found a signif-
icant association between MCP-1 and the presence of
coronary calcification after adjusting for traditional risk
factors that did not include age. This association was not
significant after additionally adjusting for age or when age
was adjusted for as a sole confounder. In contrast to the
Deo et al study, we detected a significant association
Table 2: Adjusted* spearman correlation coefficients of sICAM-1 and MCP-1 with continuous covariates
Covariates sICAM-1whites MCP-1whites MCP-1AAs†
rPrPrP
Age 0.11 <0.0001 0.35 <0.0001 0.35 <0.0001
Body mass index 0.09 0.0015 0.17 <0.0001 0.08 0.09
Waist circumference 0.09 0.0001 0.18 <0.0001 0.11 0.02
Systolic blood pressure 0.07 0.0018 0.11 <0.0001 0.03 0.49
Diastolic blood pressure 0.02 0.26 0.05 0.01 -0.03 0.45
HDL cholesterol -0.13 <0.0001 -0.19 <0.0001 -0.13 0.004
Triglycerides 0.13 <0.0001 0.22 <0.0001 0.18 0.0001
LDL cholesterol -0.04 0.07 0.04 0.05 0.06 0.19
Pack-years of smoking 0.11 <0.0001 0.02 0.34 0.03 0.57
Physical activity index -0.04 0.05 -0.11 <0.0001 -0.05 0.30
Hours of television watched/day 0.04 0.07 0.07 0.001 0.07 0.11
MCP-1 0.13 <0.0001 1.00 - 1.00 -
CRP 0.14 <0.0001 0.09 <0.0001 0.11 0.02
*Adjusted for age and gender; the analysis of age was not adjusted for covariates;
†AAs, African Americans.BMC Cardiovascular Disorders 2007, 7:30 http://www.biomedcentral.com/1471-2261/7/30
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between CAC and MCP-1 after adjusting for age and gen-
der in whites, although we also observed that the adjust-
ment for age explained most of reduction in the strength
of association between CAC and MCP-1 in the partial
adjustment model (data not presented). Nevertheless,
both studies lead to similar conclusion that MCP-1 is not
significantly associated with subclinical atherosclerotic
burden after controlling for the influence of established
CHD risk factors that include age.
Moreover, both studies consistently observed that MCP-1
was significantly lower in African Americans than in
whites. This finding, in conjunction with the previous
report of lower extent of CAC in the former group [27],
makes it reasonable to hypothesize that the association
between MCP-1 and CAC may differ between the two
racial groups. In the study by Deo et al, there was no eval-
uation of interaction effects of race on the association
between the two risk variables. Our study extends the Deo
et al study by showing that the magnitude of the associa-
tion between the two risk variables was similar between
African Americans and whites.
To our knowledge, our study is the largest to examine the
association of CAC with sICAM-1. Two smaller studies
have previously examined the association of CAC with
sICAM-1 in subjects free of clinical CHD [21,22]. The first
was conducted by Folsom et al in 360 subjects who were
selected randomly or because of a high carotid intima-
media thickness (IMT) from two field centers of the ARIC
Study [21]. Coronary calcium score measured in 1999–
2000 was analyzed in relation to sICAM-1 measured in
1987–1988. There was no significant association between
sICAM-1 and CAC category after adjusting for age, sex and
field center. The second study was conducted by Reilly et
al in 632 subjects who were recruited because of a family
Table 3: Adjusted geometric means* (95% confidence interval) of sICAM-1 and MCP-1 by categorical covariates
sICAM-1whites MCP-1whites MCP-1AAs
Gender†
Female 241.1 (236.9, 245.5) 175.8 (172.4, 179.2) 164.5 (158.8, 170.4)
Male 234.1 (229.4, 238.8) 186.0 (182.4, 189.7) 167.9 (158.4, 178.0)
P 0.01 <0.0001 0.51
Hypertension
Yes 244.4 (239.2, 249.7) 186.0 (182.0, 190.2) 168.0 (161.0, 175.3)
No 233.2 (228.9, 237.6) 177.5 (174.2, 180.9) 160.7 (151.6, 170.3)
P 0.0006 0.0004 0.19
Diabetes
Yes 256.0 (245.4, 267.1) 189.8 (182.5, 197.3) 174.6 (162.9, 187.2)
No 235.8 (232.2, 239.5) 180.0 (177.1, 182.9) 163.7 (157.6, 170.0)
P 0.0003 0.009 0.08
Smoking
Current smoker 282.6 (272.6, 293.0) 201.8 (194.1, 209.8) 171.9 (162.4, 182.0)
Former smoker 234.1 (229.1, 239.1) 175.8 (171.5, 180.1) 157.4 (149.1, 166.3)
Never Smoker 232.0 (227.7, 236.4) 180.0 (176.8, 183.2) 169.1 (161.3, 177.3)
P <0.0001 <0.0001 0.03
Alcohol Consumption
Yes 237.5 (232.9, 242.3) 176.9 (173.3, 180.6) 164.0 (156.3, 172.1)
No 237.7 (232.8, 242.6) 185.6 (182.1, 189.2) 168.2 (160.1, 176.7)
P 0.97 0.0002 0.45
Cholesterol-lowering Medication
Yes 240.0 (234.1, 246.0) 192.6 (187.3, 198.1) 176.6 (159.5, 195.5)
No‡ 242.9 (234.7, 249.7) 191.0 (185.5, 196.7) 168.9 (159.2, 179.2)
P 0.64 0.65 0.42
Aspirin Use
Yes 236.3 (230.9, 241.9) 179.2 (175.3, 183.3) 163.3 (152.0, 175.4)
No 238.2 (233.9, 242.6) 181.6 (178.4, 184.9) 167.0 (160.7, 173.6)
P 0.57 0.29 0.55
Hormone Replacement Therapy§
Yes 235.1 (228.1, 242.4) 170.9 (165.6, 176.5) 160.2 (149.7, 171.5)
No 243.6 (238.8, 248.4) 179.5 (175.7, 183.3) 167.3 (160.9, 173.9)
P 0.04 0.006 0.28
*Adjusted for age and gender unless otherwise noted below;
† Adjusted for age;
‡Those with total cholesterol ≥ 240 mg/dL and not on cholesterol-lowering medications;
§Females only.BMC Cardiovascular Disorders 2007, 7:30 http://www.biomedcentral.com/1471-2261/7/30
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history of premature CHD and a low risk factor profile
that excluded those with diabetes, total cholesterol > 300
mg/dL, cigarette smoking > one pack per day, and blood
pressure > 160/100 mm Hg [22]. sICAM-1 was signifi-
cantly and positively associated with CAC score after
adjusting for age and gender, but not after further adjust-
ment for other traditional risk factors. While the popula-
tion included in this study had a different risk factor
profile than our study, the results from the two studies are
consistent.
Our findings that the association of CAC with sICAM-1
and MCP-1 was independent of age and gender but not
independent of other established CHD risk factors suggest
that the underlying biological mechanisms that mediate
the association between sICAM-1, MCP-1 and coronary
calcification are mainly driven by established CHD risk
factors. Indeed, many stimuli that promote ICAM-1 and
MCP-1 expression are related to CHD risk factors. For
example, the expression of ICAM-1 and MCP-1 can be up-
regulated by interleukin (IL)-1, IL-6, tumor necrosis factor
Table 5: Odds ratios (95% confidence interval) of CAC > 0 or CAC ≥ 10 by MCP-1 quintile in whites
Quintiles of MCP-1
Q1 Q2 Q3 Q4 Q5 p trend
Subjects 449 449 450 449 449
Range (pg/ml) ≤ 142.1 142.2 – 167.8 167.9 – 193.7 193.8 – 230.3 > 230.3
Prevalence of CAC > 0, % 35.4 50.8 52.7 63.9 73.1
OR of CAC > 0
No Adjustment 1.00 1.89 (1.45 2.47) 2.03 (1.57 2.62) 3.28 (2.53 4.25) 5.05 (3.81 6.69) <0.0001
Partial Adjustment* 1.00 1.26 (0.92 1.73) 0.99 (0.73 1.34) 1.42 (1.03 1.96) 2.00 (1.43 2.79) <0.0001
Multivariable Adjustment** 1.00 1.12 (0.79 1.61) 0.88 (0.63 1.22) 1.12 (0.79 1.59) 1.43 (1.00 2.03) 0.048
Prevalence of CAC ≥ 10, % 21.6 31.9 34.4 43.4 54.1
OR of CAC ≥ 10
No Adjustment 1.00 1.71 (1.25 2.35) 1.93 (1.44 2.59) 2.84 (2.13 3.78) 4.45 (3.29 6.01) <0.0001
Partial Adjustment* 1.00 0.99 (0.66 1.47) 0.78 (0.54 1.14) 0.97 (0.66 1.42) 1.44 (0.97 2.14) 0.023
Multivariable Adjustment** 1.00 0.84 (0.54 1.30) 0.73 (0.48 1.11) 0.85 (0.56 1.29) 1.15 (0.76 1.75) 0.19
CAC = coronary artery calcium score;
* Adjusted for age and gender;
** Additionally adjusted for field center, BMI, SBP, diabetes, HDL and LDL cholesterol, triglycerides, physical activity index, hours of TV watched/
day, smoking status (current, former, never), pack-years of smoking, alcohol consumption, and hormone replacement therapy.
Table 4: Odds ratios (95% Confidence Interval) of CAC > 0 or CAC ≥ 10 by sICAM-1 quintile in whites
Quintiles of SICAM-1
Q1 Q2 Q3 Q4 Q5 p trend
Subjects 448 450 450 449 449
Range (ng/ml) ≤ 187.6 187.7 – 217.4 217.5 – 247.1 247.2 – 296.6 > 296.6
Prevalence of CAC > 0, % 47.3 53.1 53.8 58.8 62.8
OR of CAC > 0
No Adjustment 1.00 1.27 (0.99 1.64) 1.29 (0.99 1.68) 1.59 (1.23 2.05) 1.83 (1.40 2.40) <0.0001
Partial Adjustment* 1.00 1.22 (0.91 1.63) 1.15 (0.84 1.58) 1.49 (1.09 2.05) 1.72 (1.26 2.36) 0.0005
Multivariable Adjustment** 1.00 1.12 (0.82 1.54) 0.98 (0.70 1.36) 1.28 (0.91 1.80) 1.20 (0.86 1.69) 0.21
Prevalence of CAC ≥ 10, % 29.5 34.4 38.0 38.8 44.8
OR of CAC ≥ 10
No Adjustment 1.00 1.25 (0.94 1.66) 1.46 (1.11 1.92) 1.50 (1.15 1.96) 1.92 (1.47 2.50) <0.0001
Partial Adjustment* 1.00 1.13 (0.81 1.59) 1.36 (0.97 1.93) 1.31 (0.92 1.88) 1.88 (1.34 2.63) 0.0003
Multivariable Adjustment** 1.00 1.06 (0.75 1.50) 1.19 (0.83 1.68) 1.10 (0.76 1.59) 1.34 (0.94 1.91) 0.13
CAC = coronary artery calcium score;
* Adjusted for age and gender;
** Additionally adjusted for field center, BMI, SBP, diabetes, HDL and LDL cholesterol, triglycerides, physical activity index, hours of TV watched/
day, smoking status (current, former, never), pack-years of smoking, alcohol consumption, and hormone replacement therapy.BMC Cardiovascular Disorders 2007, 7:30 http://www.biomedcentral.com/1471-2261/7/30
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α, activated platelets, angiotensin II, shear stress, oxidized
LDL, and other oxidant species [4,5,7,28,29], all of which
have been linked to risk factors for CHD. Moreover,
sICAM-1 was reported to be associated with brachial
artery reactive hyperemia in the Framingham Offspring
Study [30]. Reactive hyperemia is a measure of microvas-
cular vasodilator function and reflects non-endothelium-
dependent and possibly endothelium-dependent vascular
function [30]. Therefore, findings from our and other sim-
ilar studies will provide valuable information in the
understanding of pathophysiological mechanisms for cor-
onary atherosclerosis.
Limitations
First, data from our study cannot provide information on
the source of circulating ICAM-1 and MCP-1 (i.e., whether
it was mainly derived from endothelial cells in the coro-
nary arteries, activated leukocytes or other sources). It is
unlikely that these markers were elevated due to major
myocardial events because participants in our study were
free of clinically apparent CHD. Second, our data are
cross-sectional and therefore we cannot determine the
temporal sequence between development of CAC and up-
regulation of inflammation biomarkers. Data from fol-
low-up studies are needed to determine the utility of these
makers in predicting the development of CAC. Third, cor-
onary calcium is a poor marker of coronary stenosis or
prognostically significant coronary disease. It has low sen-
sitivity in detecting atherosclerotic lesions that are not cal-
cified and thus it is an imperfect measure of coronary
atherosclerotic burden [31]. Fourth, only white subjects
were included in the analysis of sICAM-1 and therefore
the generalizability of the study findings for sICAM-1 to
other ethnicities is uncertain. Finally, the lack of signifi-
cant race interaction on the association between CAC and
MCP-1 needs to be interpreted with caution due to lim-
ited sample size for African Americans.
Prevalence of CAC (%) across MCP-1 tertiles by race Figure 1
Prevalence of CAC (%) across MCP-1 tertiles by race. The 
three bar pairs on the left hand side are for CAC > 0 and 
those on the right hand side are for CAC ≥ 10. The tertile 
cutpoints for MCP-1 were based on the African-American 
sample and applied to the white sample.
Table 6: Odds ratios (95% Confidence Interval) of CAC > 0 or CAC ≥ 10 by MCP-1 tertile in African Americans
Tertiles of MCP-1
T1 T2 T3 p trend
Subjects 156 157 157
Range (pg/ml) ≤ 143.6 143.7 – 184.7 >184.7
Prevalence of CAC > 0, % 34.6 51.0 59.2
OR of CAC > 0
No Adjustment 1.00 2.00 (1.21 3.32) 2.76 (1.71 4.48) <0.0001
Partial Adjustment* 1.00 1.16 (0.64 2.08) 1.25 (0.70 2.23) 0.44
Multivariable Adjustment** 1.00 1.00 (0.53 1.88) 0.82 (0.44 1.54) 0.53
Prevalence of CAC ≥ 10, % 20.5 32.5 40.1
OR of CAC ≥ 10
No Adjustment 1.00 2.02 (1.13 3.62) 2.78 (1.64 4.69) 0.0001
Partial Adjustment* 1.00 1.03 (0.52 2.04) 1.11 (0.56 2.21) 0.75
Multivariable Adjustment** 1.00 0.86 (0.41 1.82) 0.71 (0.34 1.47) 0.35
CAC = coronary artery calcium score;
* Adjusted for age and gender;
** Additionally adjusted for BMI, SBP, diabetes, HDL and LDL cholesterol, triglycerides, physical activity index, hours of TV watched/day, smoking 
status (current, former, never), pack-years of smoking, alcohol consumption, and hormone replacement therapy.BMC Cardiovascular Disorders 2007, 7:30 http://www.biomedcentral.com/1471-2261/7/30
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Conclusion
In a large population-based sample free of clinical CHD,
plasma levels of sICAM-1 and MCP-1 were significantly
associated with coronary atherosclerosis as measured by
CAC. In whites, this association was independent of age
and gender, but not of other established CHD risk factors.
In African Americans, the magnitude of association
between MCP-1 and CAC was similar to that in whites,
and there was no significant interaction of race on the
association between the two risk variables. Our study sug-
gests that sICAM-1 and MCP-1 are biomarkers of coronary
atherosclerotic burden and their association with CAC
was mainly driven by established CHD risk factors.
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